exendin based glp 1 Exendin-4 exhibits cardioprotective effects against high glucose-induced mitochondrial abnormalities: Potential role of GLP-1 receptor and mTOR signaling Immunogenicity Analysis of Exendin-4: High-Sensitivity

The World Health Organization is backing GLP-1 medications for the treatment of obesity, which some advocates hope will open up access to the drugs and improve affordability

Background Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety

Considering GLP-1 medications like Ozempic, Wegovy, or Mounjaro for weight loss

Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.

doi: 10.1097/TP.0000000000005496.

High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA say those versions come with risks.